Capital Impact Advisors LLC Purchases New Shares in United Therapeutics Co. (NASDAQ:UTHR)

Capital Impact Advisors LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,996 shares of the biotechnology company’s stock, valued at approximately $954,000. United Therapeutics comprises about 2.7% of Capital Impact Advisors LLC’s holdings, making the stock its 6th biggest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. ClariVest Asset Management LLC grew its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics during the 2nd quarter worth $30,000. Rise Advisors LLC bought a new position in shares of United Therapeutics during the 1st quarter worth $32,000. Innealta Capital LLC bought a new position in shares of United Therapeutics during the 2nd quarter worth $33,000. Finally, Benjamin F. Edwards & Company Inc. grew its stake in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the subject of several research reports. UBS Group increased their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Oppenheimer increased their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. HC Wainwright reiterated a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a research note on Thursday, August 1st. Finally, Bank of America dropped their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $357.17.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $317.05, for a total transaction of $1,141,380.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,216.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $317.05, for a total transaction of $1,141,380.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,216.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. The disclosure for this sale can be found here. In the last three months, insiders have sold 107,652 shares of company stock valued at $35,785,807. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $358.53 on Monday. The stock has a market cap of $15.95 billion, a price-to-earnings ratio of 16.95, a P/E/G ratio of 1.29 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The stock’s 50-day moving average is $342.08 and its 200 day moving average is $296.07.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the business posted $5.24 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.84 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.